Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1066884.RA0H0gQuQw79oHDzEuvea5CrnCvtXMG2ERRlws2FMHW0Y130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1066884.RA0H0gQuQw79oHDzEuvea5CrnCvtXMG2ERRlws2FMHW0Y130_assertion type Assertion NP1066884.RA0H0gQuQw79oHDzEuvea5CrnCvtXMG2ERRlws2FMHW0Y130_head.
- NP1066884.RA0H0gQuQw79oHDzEuvea5CrnCvtXMG2ERRlws2FMHW0Y130_assertion description "[Chimeric antigen receptor (CAR)-modified T cells targeting CD19 expressed by normal and malignant B cells is a unique therapy for patients with chronic lymphocytic leukemia (CLL); recent results highlight the potential of this therapy for patients with relapsed CLL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1066884.RA0H0gQuQw79oHDzEuvea5CrnCvtXMG2ERRlws2FMHW0Y130_provenance.
- NP1066884.RA0H0gQuQw79oHDzEuvea5CrnCvtXMG2ERRlws2FMHW0Y130_assertion evidence source_evidence_literature NP1066884.RA0H0gQuQw79oHDzEuvea5CrnCvtXMG2ERRlws2FMHW0Y130_provenance.
- NP1066884.RA0H0gQuQw79oHDzEuvea5CrnCvtXMG2ERRlws2FMHW0Y130_assertion SIO_000772 23561477 NP1066884.RA0H0gQuQw79oHDzEuvea5CrnCvtXMG2ERRlws2FMHW0Y130_provenance.
- NP1066884.RA0H0gQuQw79oHDzEuvea5CrnCvtXMG2ERRlws2FMHW0Y130_assertion wasDerivedFrom befree-2016 NP1066884.RA0H0gQuQw79oHDzEuvea5CrnCvtXMG2ERRlws2FMHW0Y130_provenance.
- NP1066884.RA0H0gQuQw79oHDzEuvea5CrnCvtXMG2ERRlws2FMHW0Y130_assertion wasGeneratedBy ECO_0000203 NP1066884.RA0H0gQuQw79oHDzEuvea5CrnCvtXMG2ERRlws2FMHW0Y130_provenance.